Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2016 2
2017 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

4 results
Results by year
Filters applied: . Clear all
Page 1
Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study.
Diletti R, Karanasos A, Muramatsu T, Nakatani S, Van Mieghem NM, Onuma Y, Nauta ST, Ishibashi Y, Lenzen MJ, Ligthart J, Schultz C, Regar E, de Jaegere PP, Serruys PW, Zijlstra F, van Geuns RJ. Diletti R, et al. Eur Heart J. 2014 Mar;35(12):777-86. doi: 10.1093/eurheartj/eht546. Epub 2014 Jan 6. Eur Heart J. 2014. PMID: 24394380
AIMS: We evaluated the feasibility and the acute performance of the everolimus-eluting bioresorbable vascular scaffolds (BVS) for the treatment of patients presenting with ST-segment elevation myocard
AIMS: We evaluated the feasibility and the acute performance of the everolimus-eluting bioresorbable vascular
Expanded clinical use of everolimus eluting bioresorbable vascular scaffolds for treatment of coronary artery disease.
Diletti R, Ishibashi Y, Felix C, Onuma Y, Nakatani S, van Mieghem NM, Regar E, Valgimigli M, de Jaegere PP, van Ditzhuijzen N, Fam JM, Ligthart JMR, Lenzen MJ, Serruys PW, Zijlstra F, Jan van Geuns R. Diletti R, et al. Catheter Cardiovasc Interv. 2017 Jul;90(1):58-69. doi: 10.1002/ccd.26832. Epub 2016 Nov 29. Catheter Cardiovasc Interv. 2017. PMID: 27896897
BACKGROUND: Limited data are currently available on the performance of everolimus eluting bioresorbable vascular scaffold (BVS) for treatment of complex coronary lesions representative of daily practice. METHODS: This is a prospective, mo …
BACKGROUND: Limited data are currently available on the performance of everolimus eluting bioresorbable vascular
Mid- to Long-Term Clinical Outcomes of Patients Treated With the Everolimus-Eluting Bioresorbable Vascular Scaffold: The BVS Expand Registry.
Felix CM, Fam JM, Diletti R, Ishibashi Y, Karanasos A, Everaert BR, van Mieghem NM, Daemen J, de Jaegere PP, Zijlstra F, Regar ES, Onuma Y, van Geuns RJ. Felix CM, et al. JACC Cardiovasc Interv. 2016 Aug 22;9(16):1652-63. doi: 10.1016/j.jcin.2016.04.035. Epub 2016 Jul 27. JACC Cardiovasc Interv. 2016. PMID: 27476094 Free article.
BACKGROUND: Multiple studies have proven feasibility and safety of the Absorb bioresorbable vascular scaffold (BVS) (Abbott Vascular, Santa Clara, California). ...METHODS: This is an investigator-initiated, prospective, single-center, single-arm study …
BACKGROUND: Multiple studies have proven feasibility and safety of the Absorb bioresorbable vascular scaffold (BVS) (Ab …
Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with ST-segment elevation myocardial infarction (STEMI).
Kajiya T, Liang M, Sharma RK, Lee CH, Chan MY, Tay E, Chan KH, Tan HC, Low AF. Kajiya T, et al. EuroIntervention. 2013 Aug 22;9(4):501-4. doi: 10.4244/EIJV9I4A80. EuroIntervention. 2013. PMID: 23687101 Free article.
AIMS: Recent studies have demonstrated favourable clinical outcomes for the everolimus-eluting bioresorbable vascular scaffold (BVS) ABSORB in patients with stable coronary artery disease. There are currently no data on its use in pati
AIMS: Recent studies have demonstrated favourable clinical outcomes for the everolimus-eluting bioresorbable vascula
Feedback